S1693
SU 9516
≥98% (HPLC), crystalline
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H11N3O2
化学文摘社编号:
分子量:
241.25
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
InChI
1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-7H,1H3,(H,14,15)(H,16,17)/b11-4-
SMILES string
COc1ccc2NC(=O)C(=C/c3cnc[nH]3)\c2c1
InChI key
QNUKRWAIZMBVCU-WCIBSUBMSA-N
assay
≥98% (HPLC)
form
crystalline
color
brown
solubility
DMSO: ~17 mg/mL, H2O: insoluble
Gene Information
human ... CDK2(1017), PDGFRB(5159), SRC(6714)
Application
Identified through a high-throughput screening with Cdk2. IC50=22 nM.
SU 9516 may be used to study cyclin-dependent kinase-2-dependent cell signaling.
Biochem/physiol Actions
3-substituted indoline cyclin-dependent kinase-2 (Cdk2) inhibitor. Induces apoptosis in colon carcinoma cells.
The apoptosis induced by SU 9516 in colon carcinoma cells involves dephosphorylation of pRb and cell cycle arrest in G1 or G2/M phase. In human leukemia cells, SU 9516 induces release of cytochrome c, Bax translocation and causes mitochondrial injury. It is being explored as an anti-cancer drug.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Tim Hunt
Cell cycle (Georgetown, Tex.), 7(24), 3789-3790 (2008-12-11)
Ever since it emerged that cyclin-dependent protein kinases catalyzed cell cycle transitions and with cancer seen as "a disease of the cell cycle," people have pursued the aim of testing kinase inhibitors as anti-cancer drugs. Quite early on, Laurent Meijer
Ning Gao et al.
Molecular pharmacology, 70(2), 645-655 (2006-05-05)
Mechanisms of lethality of the three-substituted indolinone and putatively selective cyclin-dependent kinase (CDK)2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) were examined in human leukemia cells. Exposure of U937 and other leukemia cells to SU9516 concentrations > or =5 microM rapidly (i.e., within 4
Yufu Zhu et al.
Journal of cellular and molecular medicine, 21(11), 2685-2694 (2017-05-05)
SH3GL2 (Src homology 3 (SH3) domain GRB2-like 2) is mainly expressed in the central nervous system and regarded as a tumour suppressor in human glioma. However, the molecular mechanism of the SH3GL2 protein involved in malignant behaviours of human glioma
Hengliang Shi et al.
Journal of cellular and molecular medicine, 18(10), 2061-2070 (2014-08-16)
Immunotherapy mediated by recombinant antibodies is an effective therapeutic strategy for a variety of cancers. In a previous study, we demonstrated that the fibroblast growth factor 1 (FGF-1)-specific recombinant antibody scFv1C9 arrests the cell cycle at the G0/G1 transition by
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持